The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
A review of Parkinson's disease
Abstract
INTRODUCTION: Parkinson's disease (PD) is one of the most common neurodegenerative disorders. Sources of data Literature search using Medline with keywords Parkinson's disease supplemented with previously published papers known to the author. AREAS OF AGREEMENT: There have been significant recent advances in the understanding of the pathogenesis of the disease. There has also been a greater realization that the disorder may be associated with significant non-motor disturbances in addition to the more commonly recognized motor complications. AREAS OF CONTROVERSY: Although there is growing circumstantial evidence, it remains to be proven whether any of the current treatments for PD have a neuroprotective effect. AREAS TIMELY FOR DEVELOPING RESEARCH: Although there is no cure, there are several management options for the early treatment of PD. As the disease progresses, further treatment options are available; however, the management of late-stage motor complications and non-motor symptoms remains particularly challenging and will benefit from further clinical research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Electrical Stimulation of the Subthalamic Nucleus in Advanced Parkinson's Disease
Limousin, P., Krack, P., Pollak, P., Benazzouz, A., Ardouin, C., Hoffmann, D., & Benabid, A.-L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810153391603 · Cited by 1,853
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service
Hughes, A. J., Daniel, S. E., Ben‐Shlomo, Y., & Lees, A. J. (2002) · Brain · doi:10.1093/brain/awf080 · Cited by 1,251
Rivastigmine for Dementia Associated with Parkinson's Disease
Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., Durif, F., Kulisevsky, J., van Laar, T., Lees, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041470 · Cited by 1,223
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Mitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
A common LRRK2 mutation in idiopathic Parkinson's disease
Gilks, W. P., Abou-Sleiman, P. M., Gandhi, S., Jain, S., Singleton, A., Lees, A. J., Shaw, K., Bhatia, K. P., Bonifati, V., Quinn, N. P., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17830-1 · Cited by 774
Chung, K. K. K., Zhang, Y., Lim, K. L., Tanaka, Y., Huang, H., Gao, J., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2001) · Nature Medicine · doi:10.1038/nm1001-1144 · Cited by 750
Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole
Frucht, S., Rogers, J. D., Greene, P. E., Gordon, M. F., & Fahn, S. (1999) · Neurology · doi:10.1212/wnl.52.9.1908 · Cited by 692
Braak, H., Bohl, J. R., Müller, C. M., Rüb, U., de Vos, R. A. I., & Del Tredici, K. (2006) · Movement Disorders · doi:10.1002/mds.21065 · Cited by 630
Dyskinesias and motor fluctuations in Parkinson's disease
Schrag, A., & Quinn, N. (2000) · Brain · doi:10.1093/brain/123.11.2297 · Cited by 600
A Controlled Trial of Rasagiline in Early Parkinson Disease: The TEMPO Study
(2002) · Archives of Neurology · doi:10.1001/archneur.59.12.1937 · Cited by 579
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
Metman, L. V., Del Dotto, P., van den Munckhof, P., Fang, J., Mouradian, M. M., & Chase, T. N. (1998) · Neurology · doi:10.1212/wnl.50.5.1323 · Cited by 514
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
Nyholm, D., Nilsson Remahl, A. I. M., Dizdar, N., Constantinescu, R., Holmberg, B., Jansson, R., Aquilonius, S. M., & Askmark, H. (2005) · Neurology · doi:10.1212/01.wnl.0000149637.70961.4c · Cited by 432
Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD
Volkmann, J., Allert, N., Voges, J., Weiss, P. H., Freund, H.-J., & Sturm, V. (2001) · Neurology · doi:10.1212/wnl.56.4.548 · Cited by 425
Genetic and environmental factors in the cause of Parkinson's disease
Warner, T. T., & Schapira, A. H. V. (2003) · Annals of Neurology · doi:10.1002/ana.10487 · Cited by 399
Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390107 · Cited by 356
Prospective prevalence of pathologic gambling and medication association in Parkinson disease
Voon, V., Hassan, K., Zurowski, M., Duff-Canning, S., de Souza, M., Fox, S., Lang, A. E., & Miyasaki, J. (2006) · Neurology · doi:10.1212/01.wnl.0000218206.20920.4d · Cited by 329
Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations
Rinne, U. K., Larsen, J. P., Siden, A., Worm-Petersen, J., & The Nomecomt Study Group* (1998) · Neurology · doi:10.1212/wnl.51.5.1309 · Cited by 326
HOW COMMON IS DEMENTIA IN PARKINSON'S DISEASE?
Brown, R. G., & Marsden, C. D. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92807-1 · Cited by 320
REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia
Vendette, M., Gagnon, J. F., Décary, A., Massicotte-Marquez, J., Postuma, R. B., Doyon, J., Panisset, M., & Montplaisir, J. (2007) · Neurology · doi:10.1212/01.wnl.0000278114.14096.74 · Cited by 283
Ravina, B. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.050682 · Cited by 273
Rektorová, I., Rektor, I., Bareš, M., Dostál, V., Ehler, E., Fanfrdlová, Z., Fiedler, J., Klajblová, H., Kulišt’ák, P., Ressner, P., et al. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00612.x · Cited by 253
Parkinson's disease in a Scottish city.
Mutch, W. J., Dingwall-Fordyce, I., Downie, A. W., Paterson, J. G., & Roy, S. K. (1986) · BMJ · doi:10.1136/bmj.292.6519.534 · Cited by 251
Schneider, S. A., Edwards, M. J., Mir, P., Cordivari, C., Hooker, J., Dickson, J., Quinn, N., & Bhatia, K. P. (2007) · Movement Disorders · doi:10.1002/mds.21685 · Cited by 247
Ubiquitin–proteasome system and Parkinson's diseases
Betarbet, R., Sherer, T. B., & Greenamyre, J. T. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.08.021 · Cited by 245
Parkinson Disease, the Effect of Levodopa, and the ELLDOPA Trial
Fahn, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.5.529 · Cited by 245
An Estimate of the Incidence of Depression in Idiopathic Parkinson's Disease
Dooneief, G., Mirabello, E., Bell, K., Marder, K., Stern, Y., & Mayeux, R. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530270125028 · Cited by 211
Beneficial effects of amantadine onL-dopa-induced dyskinesias in Parkinson's disease
Luginger, E., Wenning, G. K., B�sch, S., & Poewe, W. (2000) · Movement Disorders · doi:10.1002/1531-8257(200009)15:5<873::aid-mds1017>3.0.co;2-i · Cited by 203
Grosset, D., Taurah, L., Burn, D. J., MacMahon, D., Forbes, A., Turner, K., Bowron, A., Walker, R., Findley, L., Foster, O., et al. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.098327 · Cited by 182
Ives, N. J., Stowe, R. L., Marro, J., Counsell, C., Macleod, A., Clarke, C. E., Gray, R., & Wheatley, K. (2004) · BMJ · doi:10.1136/bmj.38184.606169.ae · Cited by 164
Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease.
Lees, A. J., & Stern, G. M. (1981) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.44.11.1020 · Cited by 163
Amantadine in Parkinson's disease
Crosby, N. J., Deane, K. H., & Clarke, C. E. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003468 · Cited by 151
Advances in neurostimulation for movement disorders
Gross, R. E., & Lozano, A. M. (2000) · Neurological Research · doi:10.1080/01616412.2000.11740667 · Cited by 147
Parkinson's disease and pesticide exposures
Dick, F. D. (2006) · British Medical Bulletin · doi:10.1093/bmb/ldl018 · Cited by 132
Psychotic Symptoms in Parkinson's Disease Patients with Dementia
Naimark, D. M. J., Jackson, E., Rockwell, E., & Jeste, D. V. (1996) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1996.tb00918.x · Cited by 97
Criteria for deep-brain stimulation in Parkinson’s disease: review and analysis
Moro, E., & Lang, A. E. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.11.1695 · Cited by 94
Dementia with Lewy bodies and Parkinson’s disease with dementia: where two worlds collide
McKeith, I. G. (2007) · Practical Neurology · doi:10.1136/jnnp.2007.134163 · Cited by 92
(2004) · PubMed · Cited by 82
Cookson, M., Xiromerisiou, G., & Singleton, A. (2005) · Current Opinion in Neurology · doi:10.1097/01.wco.0000186841.43505.e6 · Cited by 81
Brunt, E. R., Brooks, D. J., Korczyn, A. D., Montastruc, J., & Stocchi, F. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200040 · Cited by 66
Poewe, W. H., & Scherfler, C. (2003) · Movement Disorders · doi:10.1002/mds.10573 · Cited by 60
Fibrosis Associated With Dopamine Agonist Therapy in Parkinson's Disease
Müller, T. H., & Fritze, J. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200305000-00001 · Cited by 49
Neuroprotection in Parkinson's disease
Schapira, A. H. V. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70834-x · Cited by 46
Dopamine agonist therapy for Parkinson disease and pathological gambling
Imamura, A., Uitti, R. J., & Wszołek, Z. K. (2006) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2006.02.004 · Cited by 41
Cited by
GERAD1 Consortium, Pardiñas, A. F., CRESTAR Consortium, Holmans, P., Pocklington, A. J., Escott-Price, V., Ripke, S., Carrera, N., Legge, S. E., Bishop, S., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0059-2 · Cited by 1,552
Human Monocyte Subsets and Phenotypes in Major Chronic Inflammatory Diseases
Kapellos, T. S., Bonaguro, L., Gemünd, I., Reusch, N., Saglam, A., Hinkley, E. R., & Schultze, J. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02035 · Cited by 890
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
Mitochondrial Oxidative Stress—A Causative Factor and Therapeutic Target in Many Diseases
Kowalczyk, P., Sulejczak, D., Kleczkowska, P., Bukowska-Ośko, I., Kucia, M., Popiel, M., Wietrak, E., Kramkowski, K., Wrzosek, K., & Kaczyńska, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413384 · Cited by 495
The role of interleukin-6 signaling in nervous tissue
Rothaug, M., Becker-Pauly, C., & Rose-John, S. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.03.018 · Cited by 491
Metadata
- Authors
- Davie, C. A.
- Venue
- British Medical Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-02-18
- Volume
- 86
- Issue
- 1
- Pages
- 109-127
- ISSN
- 0007-1420 (ISSN-L)
- 1471-8391
- OpenAlex
- W2123714584
- Cited by
- 855
- References
- 52
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.